Loading clinical trials...
Loading clinical trials...
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety Tolerability, Pharmacokinetics, and Pharmacosymics of Single Ascending Doses of Intravenously Administerted ALTB-268 in Healthy Participants
Conditions
Interventions
ALTB-268
Placebo
Locations
1
United States
Syneos Health Clinical Research Services, LLC
Miami, Florida, United States
Start Date
November 17, 2025
Primary Completion Date
March 26, 2026
Completion Date
July 28, 2026
Last Updated
January 20, 2026
NCT07374471
NCT07271069
NCT07245394
NCT07333716
NCT06896305
NCT07269223
Lead Sponsor
AltruBio Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions